Hillsdale Investment Management Inc. Takes $225,000 Position in OptimizeRx Co. (NASDAQ:OPRX)

Hillsdale Investment Management Inc. purchased a new position in OptimizeRx Co. (NASDAQ:OPRX) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 15,700 shares of the company’s stock, valued at approximately $225,000.

A number of other large investors also recently bought and sold shares of OPRX. Kennedy Capital Management LLC purchased a new stake in OptimizeRx in the third quarter worth about $4,323,000. AWM Investment Company Inc. grew its stake in shares of OptimizeRx by 75.8% in the 3rd quarter. AWM Investment Company Inc. now owns 782,571 shares of the company’s stock worth $6,088,000 after buying an additional 337,303 shares during the last quarter. Quadrature Capital Ltd bought a new position in OptimizeRx during the 3rd quarter valued at approximately $162,000. Jump Financial LLC purchased a new position in OptimizeRx during the third quarter valued at $101,000. Finally, L2 Asset Management LLC purchased a new position in OptimizeRx during the third quarter valued at $95,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OPRX has been the topic of several recent analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 price objective on shares of OptimizeRx in a research report on Monday, April 1st. JMP Securities upped their price target on OptimizeRx from $15.00 to $16.00 and gave the company a “market outperform” rating in a report on Wednesday, May 15th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $13.00 target price on shares of OptimizeRx in a research report on Wednesday, May 15th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, OptimizeRx presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

OptimizeRx Trading Down 1.5 %

NASDAQ OPRX opened at $12.89 on Wednesday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average price of $11.16 and a 200-day moving average price of $12.46. OptimizeRx Co. has a 52 week low of $6.92 and a 52 week high of $16.65.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The business had revenue of $19.69 million during the quarter, compared to the consensus estimate of $18.66 million. OptimizeRx had a negative return on equity of 6.96% and a negative net margin of 23.10%. During the same quarter in the previous year, the business posted ($0.34) earnings per share. As a group, analysts predict that OptimizeRx Co. will post -0.49 EPS for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.